regional level, we reviewed the histories of leprosy patients treated with dapsone at the McKean Rehabilitation Centre in Chiang Mai, northern Thailand during the past 40 years.
Methods
The McKean Rehabilitation Centre in Chiang Mai, northern Thailand, has been a (church-related) treatment institute for leprosy patients since 1908. It serves patients from the whole of the northern Thailand area (population approximately 10 million). Sulphones were introduced at the Centre in 1949. In the late 1950s, 1960s and 1970s, dapsone mono therapy was the mainstay of therapy, alternating because of intolerance (which usually meant erythema nodosum leprosum (ENL)) with antibacterial drugs such as thiacetazone, thiambutosine, streptomycin, isoniazid and clofazimine. Multidrug therapy (MDT) according to the recommendations of the WHO, 10 was introduced by the end of 1982. A minor variation on the WHO regimen was made in that rifampicin 600 mg was given on 2 consecutive days per month instead of once monthly.
The available clinical data of patients treated with dapsone between 1949 and September 1988 were reviewed for the occurrence of adverse reactions attributed to dapsone. Case histories had to meet a number of criteria before the diagnosis of a true dapsone hypersensitivity reaction was made:
I, the symptoms appeared within 8 weeks after commencement of dapsone and disappeared after discontinuation of the drug; 2, the symptoms could not be ascribed to any other drug given simultaneously with dapsone; if any other drugs were taken at the same time, these could be resumed after stopping dapsone without inducing similar reactions; 3, symptoms were not attributable to lepra reactions; and 4, no other diseases liable to cause similar symptoms were diagnosed.
Final proof by trial administration of dapsone after the original reaction had subsided (as was performed in a number of cases), was not considered necessary as an absolute criterion due to the risks involved in some patients.
A hypersensitivity reaction was classified as 'Dapsone syndrome' when, apart from the above stated criteria: I, symptoms started between 2 and 8 weeks after commencement of dapsone, and 2, at least two of the fo llowing signs or symptoms were present: fe ver, skin eruption, lymphadeno pathy and liver pathology (in the form of hepatomegaly, jaundice and/or abnormal liver fu nction tests).
Results
In reviewing the clinical data accumulated at the Centre, three distinct periods could be A total of 7300 charts were examined. Table I reviews the treatment regimen policies during these periods. Hypersensitivity reactions attributed to dapsone could be divided into fo ur categories (Table 2 ). In a number of cases sufficient information was not available. These are listed separately. In 13 cases the reaction was positively proven to be caused by dapsone by giving a trial administration of the drug after the original symptoms had subsided. Table 3 gives general data of the 13 patients diagnosed as having a 'Dapsone syndrome' and Table 4 shows the main clinical signs and symptoms associated with the reaction. Finally, in Table 5 , attack rates of hypersensitivity reactions in the period 1982 to 1988 are analysed according to age group and sex. There is no significant age or sex association. A summary of five significant case histories fo llows:
Case No. I concerns a 22-year-old Thai male, was admitted on 16/5/1980 for elective surgical correction of a dropped fo ot, which had existed for 6 years. The diagnosis of tuberculoid leprosy (TT) was made and he was started on dapsone monotherapy (100 mg daily). Surgery was performed on 4/6/ 1980. Recovery was uneventful and there were no postoperative complications or infections. On 16/6/1980 an erythematous rash developed on both arms, which spread over the whole body during the fo llowing few days. On 21/6/ 1980 it was described as a general maculopapular rash with an itchy and burning sensation and diagnosed as Stevens-Johnson syndrome. Fever existed. Dapsone was now stopped and antihistamines were given, fo llowed by corticosteroids. The skin lesions progressed into a vesiculopustular rash with purpuric background. On 25/6/1980 a facial oedema and throat discomfort developed. The same afternoon the patient died suddenly. Blood examination showed thrombocytopenia and agranulocytosis.
Case No. 6 is a 28-year-old male of Hilltribe origin. He was admitted on 8/ 1 1/1984 with lepromatous leprosy (LL). The skin smear was 3·7 +. He was started on MDT-MB. Spiking fe vers were first noticed on 14/12/1984. There was no ENL and no other cause of the fe ver was fo und. On 19/12/1984 scleral icterus was seen, fo llowed by generalized adenopathy. The liver was enlarged . On 20/12/1984 a non-itchy rash appeared on the limbs (peripheral distribution) which became more generalized in the fo llowing 2 days. Differential diagnosis included typhus, typhoid, malaria, glandular fe ver, dengue, hepatitis and ENL. Liver fu nction tests showed slightly elevated SGOT, SGPT, alkaline phosphatase and bilirubin values. Malaria smears were negative. Thalidomide, chloramphenicol and 'penicillin were started but had no effect. The condition of the patient deteriorated and on 25/12/1984 he was transferred to the University Hospital of Chiang Mai under the diagnosis of possible Dapsone syndrome. The patient died on 2/ 1 /1985 due to hepatic failure and toxic shock. Case No. 9 is a 76-year-old Chinese man who was admitted on 28/4/ 1987 after borderline lepromatous leprosy (BL) was diagnosed (skin smear 3·7 +). He was started on MDT -MB. Low grade fe vers developed n 20/5/1987, but no signs of ENL Or other causes for the fe ver were fo und. Penicillin was started orally on 26/5/ 1987, but this had no effect and was stopped on 28/5/1987. Before other examinations could be initiated, his condition deteriorated rapidly. He developed sOres in the mouth, a diffuse erythematous rash appeared and he became jaundiced. On 31/5/1 987 dapsone was stopped and he was transferred to the University Hospital of Chiang Mai where he died on 7/6/1987 because of hepatic failure. Case No. 10 concerns a 31-year-old male of Hilltribe ongm. He was diagnosed with lepromatous leprosy (LL; skin smear 2·8 +). MDT-MB was started and he returned home on the same day (18/5/1987). On 18/6/1987 he presented himself at the University Hospital of Chiang Mai with high grade fever and a generalized maculopapular rash. Dapsone syndrome was suspected, dapsone and rifampicin were discontinued, a course of prednisolone was started and he was referred back to the Centre. On 3/7/1987 jaundice was noticed and liver function tests showed slight elevations of SGOT, SGPT and alkaline phosphatase. Serological tests for Hepatitis A and B were negative. The patient recovered well and continued treatment on clofazimine. Rifampicin has not yet been resumed. hypopigmentated patches on his face; the (R) great auricular nerve and (R) ulnar nerve were enlarged. Skin smears showed no acid-fast bacteria. He was diagnosed as having tuberculoid leprosy (TT) and started on MDT-PB (child dose: half strength). On 2/ 1 1/1987 he returned with fever and abdominal pain and swelling, accompanied by nausea and vomiting. There was a marked erythematous papular rash with exfoliation. Symptoms had started 4 days previously. The liver was enlarged and ascitis existed. All therapy was stopped and the patient was sent to the University Hospital and treated for Dapsone syndrome with prednisolone. This had to be continued for 2 months, but eventually there was a good recovery and the boy continued with rifampicin and c10fazimine afterwards without further problems.
Discussion
Dapsone syndrome is basically a clinical diagnosis and often made and treated under 'field conditions'. Thorough analysis of haematological, immunological and biochemical features of hypersensitivity reactions to dapsone was beyond the scope of this retrospective study.
The information gathered between 1949 and 1969 is too incomplete for valid analysis. In the period between 1970 and 1982, 2350 new, previously untreated patients were started on dapsone. Hypersensitivity was observed in 8 patients, of which 6 had an early onset with skin eruptions only (incidence 0'3%). If we include the other 6 cases of dubious diagnosis, the incidence is 0·6%. After implementation of MDT in 1982, 19 cases of dapsone hypersensitivity have been diagnosed: 12 were labelled as Dapsone syndrorne, 3 as early onset and 4 as delayed onset with skin eruptions only. In this period, 524 new, previously untreated, patients were started on MDT. The incidence of dapsone hypersensitivity reaction is thus 3·6%, a tenfold rise compared with the 1970-1982 period.
A number of important factors can be mentioned as possibly contributing to the observed rise: 1 Increased awareness. Although experience with side -effects from dapsone have always existed in the Centre, it can be argued that awareness amongst medical staff was enhanced by the sudden tragic death of a young patient in 1980 (No. 1, Tables 3 and 4 ) . The increase in the number of reports in literature since 1980 may also have contributed to greater awareness. Besides this, the implementation of MDT has intensified monitoring of patients starting treatment.
2 Low dose regimens of dapsone befo re 1976. Table I shows that it was common practice before 1976 to start treatment with low amounts of dapsone and gradually increase the dosage. One wonders if this policy desensitized patients to the drug. Successful desensitization to dapsone in a comparable way was described by Browne in 1963.
II
3 Quality of dapsone. Changes in manufacturing since 1949 and even storage time might explain chemical changes leading to hypersensitivity. This needs to be clarified. 4 Combination with other an tileprosy drugs. The combination of high dose dapsone with rifampicin seems to be the common factor when comparing the various drug regimens to explain the increased incidence of hypersensitivity reactions. Dapsone 50 or 100 mg daily combined with c10fazimine 100 mg three times per week was used between 1976 and 1982 without a noticeable increase of reactions.
Since the introduction of MDT, hypersensitivity reactions have been seen in both patients on MDT MB (with clofazimine) and MDT -PB (without clofazimine).
The question is whether rifampicin sensitizes certain susceptible people to dapsone, especially in the combination of dosages used in MDT.
Our study shows an apparent increase in hypersensitivity reactions to dapsone after the introduction of MDT. We believe, certainly within the context of the Centre, that this observation reflects a true rise in incidence. The possibility of rifampicin as a contributing fa ctor to the increase of dapsone reactions is suggestive and should be seriously considered and investigated. In our experience, no patients who were previously on dapsone monotherapy, developed a hypersensitivity reaction after beginning MDT. It could be advised that MDT treatment schedules are adapted in such a way that dapsone is given at least 8 weeks before starting rifampicin.
